Triplex Checkpoint Inhibitors Therapy for Advanced Solid Tumors
Status:
Recruiting
Trial end date:
2025-10-30
Target enrollment:
Participant gender:
Summary
This trial is designed to investigate the safety, response rates and survival outcomes of
patients with advanced solid tumors by infusion of CTLA4, PD1 and PDL1 antibodies combination
through venous (IV), artery (IA) or intra-tumor (IT).
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Second Affiliated Hospital of Guangzhou Medical University